Zoetis Inc. (NYSE:ZTS) Shares Sold by Wells Fargo & Company MN

Wells Fargo & Company MN lowered its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 5.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,932,698 shares of the company's stock after selling 340,735 shares during the quarter. Wells Fargo & Company MN owned about 1.31% of Zoetis worth $966,615,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Atlantic Edge Private Wealth Management LLC boosted its stake in Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after acquiring an additional 140 shares in the last quarter. Rakuten Securities Inc. boosted its position in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after purchasing an additional 166 shares in the last quarter. Dunhill Financial LLC boosted its position in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock worth $33,000 after purchasing an additional 75 shares in the last quarter. Murphy & Mullick Capital Management Corp purchased a new position in Zoetis during the 4th quarter worth $44,000. Finally, Asset Planning Inc acquired a new position in Zoetis during the 4th quarter valued at about $58,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on ZTS shares. Barclays boosted their price target on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. Piper Sandler upped their target price on Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. Stifel Nicolaus reduced their target price on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Finally, UBS Group began coverage on Zoetis in a report on Monday, December 9th. They set a "neutral" rating and a $196.00 target price for the company. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $215.90.

Remove Ads

Zoetis Price Performance

Shares of Zoetis stock traded down $2.70 during mid-day trading on Monday, reaching $149.03. 4,263,169 shares of the stock traded hands, compared to its average volume of 2,601,968. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a fifty-two week low of $144.07 and a fifty-two week high of $200.33. The stock has a market capitalization of $66.73 billion, a PE ratio of 27.24, a PEG ratio of 2.78 and a beta of 0.92. The business has a 50-day moving average of $165.71 and a 200 day moving average of $173.26.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. On average, analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.34%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio is presently 36.56%.

Insider Buying and Selling

In other news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is currently owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.